Rosetta Genomics to Host Business Update Conference Call on April 1, 2014
March 25 2014 - 2:50PM
Marketwired
Rosetta Genomics to Host Business Update Conference Call on April
1, 2014
2013 Annual Report on Form 20-F to Be Filed With SEC
PRINCETON, NJ and REHOVOT, ISRAEL--(Marketwired - Mar 25, 2014)
- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer
and provider of microRNA-based molecular diagnostics and
therapeutics, today announced that following the close of the U.S.
stock market on Monday, March 31, 2014, the Company will file its
Annual Report on Form 20-F for the year ended December 31, 2013
with the U.S. Securities and Exchange Commission ("SEC"). The Form
20-F will include audited annual consolidated financial statements,
as well as additional information regarding the Company. The Form
20-F will be available at www.sec.gov and at
www.rosettagenomics.com.
Kenneth A. Berlin, President and Chief Executive Officer of
Rosetta Genomics, and Ron Kalfus, Chief Financial Officer of
Rosetta Genomics, will host a conference call on Tuesday, April 1,
2014 at 10:00 a.m. Eastern time (7:00 a.m. Pacific time) to provide
an update on the Company's business and respond to questions.
Individuals interested in listening to the conference call may
do so by dialing (866) 239-5859, or for international callers (702)
495-1913. The conference ID number is 19429704. The call
is also being webcast, and can be accessed on the investor
relations section of the Company's Web site at
www.rosettagenomics.com and also at www.streetevents.com.
A telephone replay will be available through April 8, 2014 by
dialing (855) 859-2056 or for international callers (404) 537-3406,
and entering the Conference ID number 19429704. The webcast
will be available for 30 days following the completion of the
call.
About Rosetta Cancer Testing Services Rosetta Cancer Tests are a
series of microRNA-based diagnostic testing services offered by
Rosetta Genomics. The Rosetta Cancer Origin Test™ can accurately
identify the primary tumor type in primary and metastatic cancer
including cancer of unknown or uncertain primary (CUP). The Rosetta
Mesothelioma Test™ diagnoses mesothelioma, a cancer connected to
asbestos exposure. The Rosetta Lung Cancer Test™ accurately
identifies the four main subtypes of lung cancer using small
amounts of tumor cells. The Rosetta Kidney Cancer Test™ accurately
classifies the four most common kidney tumors: clear cell renal
cell carcinoma (RCC), papillary RCC, chromophobe RCC and
oncocytoma. Rosetta's assays are designed to provide objective
diagnostic data; it is the treating physician's responsibility to
diagnose and administer the appropriate treatment. In the U.S.
alone, Rosetta Genomics estimates that 200,000 patients a year may
benefit from the Rosetta Cancer Origin Test™, 60,000 from the
Rosetta Mesothelioma Test™, 65,000 from the Rosetta Kidney Cancer
Test™ and 226,000 patients from the Rosetta Lung Cancer
Test™. The Company's assays are offered directly by Rosetta
Genomics in the U.S., and through distributors around the world.
For more information, please visit www.rosettagenomics.com. Parties
interested in ordering the test can contact Rosetta Genomics at
(215) 382-9000.
About Rosetta Genomics Founded in 2000, Rosetta's integrative
research platform combining bioinformatics and state-of-the-art
laboratory processes has led to the discovery of hundreds of
biologically validated novel human microRNAs. Building on its
strong patent position and proprietary platform technologies,
Rosetta is working on the application of these technologies in the
development and commercialization of a full range of microRNA-based
diagnostic tools and therapeutics. Rosetta currently commercializes
a full range of microRNA-based molecular
diagnostics. Rosetta's cancer testing services are
commercially available through its Philadelphia-based
CAP-accredited, CLIA-certified lab. Frost & Sullivan
recognized Rosetta Genomics with the 2012 North American Next
Generation Diagnostics Entrepreneurial Company of the Year
Award. For more information, please visit
www.rosettagenomics.com.
Forward-Looking Statement Disclaimer Various statements in this
release concerning Rosetta's future expectations, plans and
prospects, including without limitation, Rosetta filing its
year-end statements on March 31, 2014, constitute forward-looking
statements for the purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by these forward-looking
statements as a result of various important factors, including
those risks more fully discussed in the "Risk Factors" section of
Rosetta's Annual Report on Form 20-F for the year ended December
31, 2012 as filed with the SEC. In addition, any forward-looking
statements represent Rosetta's views only as of the date of this
release and should not be relied upon as representing its views as
of any subsequent date. Rosetta does not assume any obligation to
update any forward-looking statements unless required by law.
Company Contact: Rosetta Genomics Ken Berlin President & CEO
(609) 419-9003 investors@rosettagenomics.com Investor Contacts: LHA
Anne Marie Fields (212) 838-3777 afields@lhai.com or Bruce Voss
(310) 691-7100 bvoss@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Apr 2023 to Apr 2024